Seagen’s Adcetris (brentuximab vedotin) Receives the US FDA’s Approval for High-Risk Hodgkin Lymphoma
Shots:
- The US FDA has approved Adcetris for high-risk cHL in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged ≥2yrs.
- The approval was based on the P-III (NCI)-sponsored study (AHOD1331), conducted by the Children's Oncology Group (COG) & funded by NCI evaluating Adcetris + CT (AVE-PC) vs CT (ABVE-PC) in 587 patients aged 2-21yrs. across 151 institutions. The results showed a superior EFS over ABVE-PC & 59% reduction in risk of disease progression or relapse, second cancer, or death
- Seagen & Takeda collaborated to develop Adcetris where Seagen has US & Canadian commercialization rights, and Takeda has rights to commercialize the product globally
Ref: Businesswire | Image: Seagen
Click here to read the full press release